Seth Lederman is a physician, scientist and specialty pharmaceuticals entrepreneur. He is a co-founder and the current President and Chairman of Tonix Pharmaceuticals, a specialty pharmaceutical product development and commercialization company.
Biography
Lederman earned his bachelor's degree in Chemistry from Princeton University where he graduated cum laude in 1979. He completed his M.D. from Columbia University in 1983 and continued his training at the Columbia Presbyterian Medical Center until 1986. Lederman became instructor at Columbia in 1985, Assistant Professor in 1988 and Associate Professor with tenure in 1996. From October 30, 2015 until November 1, 2016 he took a leave of absence and left Columbia in April 2017. In addition to his research, he served as attending physician in the Edward Daniels Faulkner Arthritis Clinic at Columbia Presbyterian Hospital from 1988-1996 and served as Associate Attending physician at Columbia Presbyterian Hospital until 2000. As Assistant Professor at Columbia, Dr. Lederman discovered the CD40-Ligand and elucidated the molecular basis of T cell helper function. Lederman also collaborated with Professor David Baltimore in identifying and functionally characterizing the CD40 signaling molecule, TRAF-3. Dr. Lederman’s “early work on HIV contributed to the understanding of how the V3 loop of HIV gp120 was involved in fusion with CD4 cell membranes, an early and essential event in viral entry and infection”. Lederman founded Targent Pharmaceuticals, which sold levoleucovorin to Spectrum Pharmaceuticals, which markets it as Fusilev. Lederman co-founded and served as a managing partner of Konanda Pharma Partners and Konanda Pharma Fund I, LP, and its wholly owned operating companies, Validus and Fontus Pharmaceuticals Inc. Validus acquired Fontus and markets Equetro, Marplan and Rocaltrol. Lederman founded Tonix Pharmaceuticals which is developing TNX-102 SL for post-traumatic stress disorder. FDA awarded TNX -102 SL “Breakthrough Therapy” designation for PTSD because its effects in military-related PTSD have the potential to be improvements over existing therapies
Discovery of CD40-ligand (CD154): the Molecular Basis of T Helper Function
As Assistant Professor at Columbia, Lederman discovered the CD40-Ligand and elucidated the molecular basis of T cell helper function. Lederman's work on the led to the development of therapeutic candidates for autoimmune diseases and organ transplant rejection in collaboration with Biogen and UCB/CellTech. Dartmouth College challenged the CD40-Ligand patents, but the challenge was rejected on all claims. UCB is currently in Phase 2 trials with dapirolizumab pegol. Transcriptional changes in Dapirolizumab pegol treated Systemic Lupus Erythematosus patients were recently reported.
TNX-801 is a new potential vaccine for smallpox. TNX-801 is a synthetic form of horsepox, which is an otherwise extinct virus. Evolutionary analysis of modern vaccines indicates that the vaccine isolated and used by Edward Jenner to vaccinate against smallpox was either horsepox or something quite similar. A 1902 sample of vaccinia smallpox vaccine was characterized and found to be 99.7% similar to horsepox, further supporting the connection with Jenner's vaccine. The synthesis of horsepox was a collaboration with David Evans and Ryan Noyce at the University of Alberta in Edmonton, Alberta, Canada. TNX-801 or horsepox is the first poxvirus, or poxviridae, to be synthesized and provides a platform for developing new vaccines against infectious disease and cancer. The finding that a horsepox vaccine was in clinical use in the U.S. in 1902 to protect against smallpox provides strong support for the efficacy of TNX-801 horsepox vaccine to protect against smallpox.
International Biotechnology Policy and Cooperation
